TransMedics Group (TMDX) Investor Day 2024 summary

Strategic vision and growth initiatives

• Aims to surpass 10,000 annual transplants, expanding into kidney and international markets by 2029, with pilot NOP programs in Europe as early as 2026.

• Growth strategy centers on next-gen OCS technology for lung, heart, and kidney, launching 2025–2029, focusing on superior clinical outcomes, extended preservation, and digital integration.

• Digital ecosystem (NOP Connect) will streamline case management, billing, and transparency, enhancing operational efficiency and scalability.

• NOP network and logistics infrastructure are key to scaling operations and supporting national and international growth.

• Financial discipline and self-funding are emphasized, with 2025 revenue growth guidance of 20–25% and a focus on operational efficiency.

Technology and clinical advancements

• Next-gen OCS Lung and Heart programs focus on prolonged perfusion, superior post-transplant outcomes, and enabling daytime transplants.

• Clinical trials demonstrate significant reductions in edema, ischemic injury, and post-transplant complications compared to cold storage.

• OCS technology has led to the highest reported utilization rates for DBD and DCD donor organs and improved patient survival.

• Published evidence in top medical journals supports non-inferior or superior outcomes for OCS-preserved organs.

• OCS Kidney program in development, with FDA trials starting in 2027 and launch targeted for 2029.

Clinical and commercial execution

• OCS technology has driven double-digit growth in U.S. heart and liver transplants, with 75% DCD heart and 55% DCD liver market share.

• Daytime transplant procedures have transformed liver programs, improving outcomes, cost efficiency, and surgeon quality of life; this model will be replicated for heart and lung.

• Next-gen lung and heart programs target edema reduction, longer preservation, and head-to-head superiority trials versus cold storage, with FDA collaboration on innovative, blinded trial designs.

• Penetration remains low in many centers, especially for heart and lung, representing significant growth potential as clinical data and network effects drive adoption.

• Competitive threats from NRP and cold perfusion are seen as limited due to cost, scalability, and clinical outcome advantages of OCS and NOP.